Controversies in pregnancy and congenital heart disease

Congenital Heart Disease

Volumn 1, Issue 1-2, 2006, Pages 27-34

  Swan, Lorna ^a,d   Lupton, Martin ^b   Anthony, John ^c   Yentis, Steve M ^b   Steer, Philip J ^b   Gatzoulis, Michael A ^b,d  

^a WESTERN INFIRMARY   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Congenital heart disease; Delivery; Maternal; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; FLECAINIDE; HEMOGLOBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OXYGEN; PHENYTOIN; PROCAINAMIDE; WARFARIN;

ADULT; ANTICOAGULATION; AORTA SUBVALVULAR STENOSIS; ARTICLE; BJOERK SHILEY VALVE PROSTHESIS; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL HEART DISEASE; CYANOSIS; DIGEORGE SYNDROME; DISEASE ASSOCIATION; DOSE RESPONSE; EISENMENGER COMPLEX; ELECTIVE SURGERY; EMBRYOPATHY; FAMILY PLANNING; FEMALE; FETAL HEMORRHAGE; GENETIC COUNSELING; GREAT VESSELS TRANSPOSITION; GROWTH RETARDATION; HEALTH HAZARD; HEART ATRIUM FLUTTER; HEART BLOCK; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SEPTUM DEFECT; HEART VALVE PROSTHESIS; HEMOGLOBIN DETERMINATION; HIGH RISK PREGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; HYPOTHYROIDISM; HYPOXIA; INTRAUTERINE GROWTH RETARDATION; LUNG ATRESIA; MARFAN SYNDROME; MATERNAL WELFARE; MENTAL DEFICIENCY; MUSTARD OPERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN SATURATION; PATIENT COUNSELING; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SAFETY; SPINAL HEMATOMA; SPONTANEOUS ABORTION; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; TERATOGENESIS; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; ANTICOAGULANTS; CESAREAN SECTION; FEMALE; FETAL GROWTH RETARDATION; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY, HIGH-RISK;

EID: 33644969953     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2006.00005.x     Document Type: Article

References (53)

1. Why Mothers Die 2000-2002. The Confidential Enquiries Into Maternal Deaths in the United Kingdom. London: RCOG Press; 2004. Available at: http://www.cemach.org.uk/publications/WMD2000-2002. Accessed February 2, 2005.
2. Gei AF, Hankins GD. Cardiac disease and pregnancy. Obstet Gynecol Clin North Am. 2001; 28: 465-512.
3. Pattinson B. Saving mothers. Second report on confidential enquiries into maternal deaths in South Africa 1999-2001. Department of Health, Republic of South Africa, Government Printer; 2003.
4. Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart. 2001; 85: 438-443.
5. Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001; 104: 515-521.
6. Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation. 1997; 96: 2789-2794.
7. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation. 1994; 89: 2673-2676.
8. Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and mortality among premature neonates. Am J Obstet Gynecol. 2004; 191: 481-487.
9. Botto LD, May K, Fernhoff PM, et al. A population-based study of the 22q11.2 deletion: Phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003; 112: 101-107.
10. Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol. 1998; 32: 492-498.
11. Antman EM. Current diagnosis and prescription for Marfan syndrome: When to operate. J Card Surg. 1994; 9 (2 suppl): 174-176.
12. Immer FF, Bansi AG, Immer-Bansi AS, et al. Aortic dissection in pregnancy: Analysis of risk factors and outcome. Ann Thorac Surg. 2003; 76: 309-314.
13. Hart MV, Morton MJ, Hosenpud JD, Metcalfe J. Aortic function during normal human pregnancy. Am J Obstet Gynecol. 1986; 154: 887-891.
14. Groenink M, Lohuis TA, Tijssen JG, et al. Survival and complication free survival in Marfan's syndrome: Implications of current guidelines. Heart. 1999; 82: 499-504.
15. Silverman DI, Gray J, Roman MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol. 1995; 26: 1062-1067.
16. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994; 330: 1335-1341.
17. Rossiter JP, Repke JT, Morales AJ, Murphy EA, Pyeritz RE. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol. 1995; 173: 1599-1606.
18. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: A meta-analysis. Lancet. 2000; 355 (9198): 87-92.
19. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997; 79: 1436-1438.
20. Steer PJ. Pregnancy and contraception. In: Gatzoulis MA, Swan L, Therrien J, Pantely GA, eds. Adult Congenital Heart Disease: A Practical Guide. Oxford: BMJ/Blackwell Publishing Ltd; 2005: 16-35.
21. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998; 31: 1650-1657.
22. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998; 19: 1845-1855.
23. Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol. 1998; 105: 921-922.
24. Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, Willan AR. Planned caesarean section versus planned vaginal birth for breech presentation at term: A randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet. 2000; 356 (9239): 1375-1383.
25. Rao TL, El-Etr AA. Anticoagulation following placement of epidural and subarachnoid catheters: An evaluation of neurologic sequelae. Anesthesiology. 1981; 55: 618-620.
26. Secher NJ, Arnsbo P, Wallin L. Haemodynamic effects of oxytocin (syntocinon) and methyl ergometrine (methergin) on the systemic and pulmonary circulations of pregnant anaesthetized women. Acta Obstet Gynecol Scand. 1978; 57: 97-103.
27. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: Hematologic management. Ann Intern Med. 1988; 109: 406-413.
28. Tempe DK, Virmani S. Coagulation abnormalities in patients with cyanotic congenital heart disease. J Cardiothorac Vasc Anesth. 2002; 16: 752-765.
29. Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet Gynecol. 2002; 99: 502-506.
30. Bates SM, Ginsberg JS. Anticoagulants in pregnancy: Fetal effects. Baillieres Clin Obstet Gynaecol. 1997; 11: 479-488.
31. Ginberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med. 2003; 163: 694-698.
32. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002; 99: 35-40.
33. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33: 1637-1641.
34. Lovenox Injection [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals Inc; 2002.
35. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004; 191: 1024-1029.
36. Reimold SC, Rutherford JD. Vavlular heart disease in pregnancy. N Engl J Med 2003; 349: 52-60.
37. Arias F, Pineda J. Aortic stenosis and pregnancy. J Reprod Med. 1978; 20: 229-232.
38. Silversides CK, Colman JM, Sermer M, Farine D, Siu SC. Early and intermediate-term outcomes of pregnancy with congenital aortic stenosis. Am J Cardiol. 2003; 91: 1386-1389.
39. Angel JL, Chapman C, Knuppel RA, Morales WJ, Sims CJ. Percutaneous balloon aortic valvuloplasty in pregnancy. Obstet Gynecol. 1988; 72: 438-440.
40. Pomini F, Mercogliano D, Cavalletti C, Caruso A, Pomini P. Cardiopulmonary bypass in pregnancy. Ann Thorac Surg. 1996; 61: 259-268.
41. Suntharalingam G, Dob D, Yentis SM. Obstetric epidural analgesia in aortic stenosis: A low-dose technique for labour and instrumental delivery. Int J Obstet Anesth. 2001; 10: 129-134.
42. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001; 24: 116-130.
43. Therrien J, Barnes I, Somerville J. Outcome of pregnancy in patients with congenitally corrected transposition of the great arteries. Am J Cardiol. 1999; 84: 820-824.
44. Chugh R, Perloff JK, Ludbrook PA, et al. The impact of pregnancy on function of the subaortic morphologic right ventricle in d or l transposition of the great arteries. American Heart Association; 2001. Abstract.
45. Lilford RJ, Van Coeverden deGroot HA, Moore PJ, Bingham P. The relative risks of caesarean section (intrapartum and elective) and vaginal delivery: A detailed analysis to exclude the effects of medical disorders and other acute preexisting physiological disturbances. Br J Obstet Gynaecol. 1990; 97: 883-892.
46. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002; 109: 1406-1407.
47. Burg JR, Dodek A, Kloster FE, Metcalfe J. Alterations of systolic time intervals during pregnancy. Circulation. 1974; 49: 560-564.
48. Clapp JF, Seaward BL, Sleamaker RH, Hiser J. Maternal physiologic adaptations to early human pregnancy. Am J Obstet Gynecol. 1988; 159: 1456-1460.
49. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989; 256: 1060-1065.
50. Edouard DA, Pannier BM, London GM, Cuche JL, Safar ME. Venous and arterial behaviour during normal pregnancy. Am J Physiol. 1998; 274: 1605-1612.
51. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J. 2003; 24: 761-781.
52. Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease. Circulation. 2002; 105: 217-2184.
53. Burn J, Brennan P, Little J, et al. Recurrence risks in offspring of adults with major heart defects: Results from first cohort of British collaborative study. Lancet. 1998; 351 (9099): 311-316.